cetylpyridinium chloride anhydrous has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, WL; Chu, NN; Li, XN; Xu, HR; Zhu, JR | 1 |
1 trial(s) available for cetylpyridinium chloride anhydrous and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
The difference in pharmacokinetics and pharmacodynamics between extended-release fluvastatin and immediate-release fluvastatin in healthy Chinese subjects.
Topics: Adult; Asian People; China; Delayed-Action Preparations; Drug Compounding; Fatty Acids, Monounsaturated; Fluvastatin; Health; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Tablets; Time Factors; Young Adult | 2012 |